Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Development of Artificial Intelligence Tools for the Detection of Stress Markers and Consideration of Stress States in the Monitoring of Subjects With Type 1 Diabetes

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Stress refers to all the reactions of an organism subjected to exogenous or endogenous stress. In the context of diabetes, stress plays a critical role. There are two forms of stress: acute and chronic, both of which can have a significant impact on patients' glycaemic control. Acute stress, if repeated, can cause rapid increases in blood glucose levels, while chronic stress can lead to insulin resistance. It is therefore essential to develop tools for recognising and quantifying stress states specific to patients with diabetes. These tools would provide a better understanding of the role of stress in diabetes management, paving the way for more targeted therapeutic interventions and improving patients' quality of life. We are currently training algorithms using advanced machine learning and artificial intelligence techniques to recognise and quantify stress states using existing databases, including voice and physiological data. These technological advances will make it possible to identify moments of stress more accurately and provide appropriate responses, thereby contributing to better diabetes management. The SMART-T1D study is an ancillary study of the EVASTRESS study.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient who has signed the SMART-T1D free and willing to sign a consent form form - Patient able to speak and read French Who Should NOT Join This Trial: - Mute patient. - Patient with severe speech problems that may prevent voice recordings from being made. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patient who has signed the SMART-T1D free and informed consent form * Patient able to speak and read French Exclusion Criteria: * Mute patient. * Patient with severe speech problems that may prevent voice recordings from being made.

Treatments Being Tested

OTHER

Voice recording 4 times a day

* Morning (first recording): Text reading (article 25.1 of the Declaration of Human Rights). * Noon (second recording): Counting from 1 to 20 at normal speed * Evening (third recording): Prolonged phonation of the vowel 'a' without catching your breath. * Bedtime (fourth recording): Free expression describing stressful moments of the day and their impact on diabetes management, for at least 30 seconds.

Locations (5)

Rennes University Hospital
Rennes, France, France
Strasbourg University Hospital
Strasbourg, France, France
Angers University Hospital
Angers, Site Principal Investigator, France
CERITD (Centre d'Etudes et de Recherches pour l'Intensification du Traitement du Diabète)
Évry, France
Grenoble University Hospital
Grenoble, France